Steroid Minimization in Adults with Minimal Change Disease

BACKGROUND: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recogn...

Descripción completa

Detalles Bibliográficos
Autores principales: Koirala, Abbal, Jefferson, J. Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677715/
https://www.ncbi.nlm.nih.gov/pubmed/36751385
http://dx.doi.org/10.1159/000517626
_version_ 1784833865053896704
author Koirala, Abbal
Jefferson, J. Ashley
author_facet Koirala, Abbal
Jefferson, J. Ashley
author_sort Koirala, Abbal
collection PubMed
description BACKGROUND: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recognized and commonly encountered with the high doses and recurrent courses used in MCD. SUMMARY: In this review, we will discuss the standard therapy of MCD in adults and then describe new therapeutic options in induction therapy and treatment of relapses in MCD, minimizing the exposure to GCs. KEY MESSAGES: Steroid minimization strategies may decrease adverse effects in the treatment of MCD.
format Online
Article
Text
id pubmed-9677715
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-96777152023-02-06 Steroid Minimization in Adults with Minimal Change Disease Koirala, Abbal Jefferson, J. Ashley Glomerular Dis Review Article BACKGROUND: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recognized and commonly encountered with the high doses and recurrent courses used in MCD. SUMMARY: In this review, we will discuss the standard therapy of MCD in adults and then describe new therapeutic options in induction therapy and treatment of relapses in MCD, minimizing the exposure to GCs. KEY MESSAGES: Steroid minimization strategies may decrease adverse effects in the treatment of MCD. S. Karger AG 2021-07-29 /pmc/articles/PMC9677715/ /pubmed/36751385 http://dx.doi.org/10.1159/000517626 Text en Copyright © 2021 by The Author(s) Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
spellingShingle Review Article
Koirala, Abbal
Jefferson, J. Ashley
Steroid Minimization in Adults with Minimal Change Disease
title Steroid Minimization in Adults with Minimal Change Disease
title_full Steroid Minimization in Adults with Minimal Change Disease
title_fullStr Steroid Minimization in Adults with Minimal Change Disease
title_full_unstemmed Steroid Minimization in Adults with Minimal Change Disease
title_short Steroid Minimization in Adults with Minimal Change Disease
title_sort steroid minimization in adults with minimal change disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677715/
https://www.ncbi.nlm.nih.gov/pubmed/36751385
http://dx.doi.org/10.1159/000517626
work_keys_str_mv AT koiralaabbal steroidminimizationinadultswithminimalchangedisease
AT jeffersonjashley steroidminimizationinadultswithminimalchangedisease

Ejemplares similares